IRIS
GREMESE, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.645
NA - Nord America 4.132
SA - Sud America 1.108
EU - Europa 778
AF - Africa 103
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 1
Totale 11.776
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.975
SG - Singapore 3.772
BR - Brasile 906
CN - Cina 699
VN - Vietnam 506
HK - Hong Kong 187
IT - Italia 117
IN - India 112
GB - Regno Unito 98
DE - Germania 97
AR - Argentina 74
RU - Federazione Russa 70
BD - Bangladesh 67
CA - Canada 66
FR - Francia 62
MX - Messico 60
IQ - Iraq 55
FI - Finlandia 48
EC - Ecuador 38
CZ - Repubblica Ceca 36
IE - Irlanda 34
SE - Svezia 33
NL - Olanda 31
JP - Giappone 30
PK - Pakistan 30
ZA - Sudafrica 30
ID - Indonesia 29
PL - Polonia 25
CO - Colombia 24
TR - Turchia 24
UA - Ucraina 24
VE - Venezuela 21
ES - Italia 18
LT - Lituania 17
MA - Marocco 17
PH - Filippine 15
MY - Malesia 14
PY - Paraguay 14
AT - Austria 13
SA - Arabia Saudita 13
CL - Cile 12
NG - Nigeria 12
AZ - Azerbaigian 11
BE - Belgio 11
KE - Kenya 11
UZ - Uzbekistan 11
NP - Nepal 10
AE - Emirati Arabi Uniti 9
IL - Israele 8
AU - Australia 7
EG - Egitto 7
JO - Giordania 7
KZ - Kazakistan 7
UY - Uruguay 7
CH - Svizzera 6
LV - Lettonia 6
PE - Perù 6
BO - Bolivia 5
DZ - Algeria 5
HN - Honduras 5
IR - Iran 5
RO - Romania 5
TT - Trinidad e Tobago 5
DK - Danimarca 4
OM - Oman 4
SN - Senegal 4
TH - Thailandia 4
TN - Tunisia 4
AL - Albania 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GR - Grecia 3
GT - Guatemala 3
HR - Croazia 3
JM - Giamaica 3
PA - Panama 3
SK - Slovacchia (Repubblica Slovacca) 3
AO - Angola 2
BG - Bulgaria 2
CG - Congo 2
CI - Costa d'Avorio 2
GE - Georgia 2
KG - Kirghizistan 2
KW - Kuwait 2
MN - Mongolia 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
RS - Serbia 2
SI - Slovenia 2
SY - Repubblica araba siriana 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
CU - Cuba 1
GD - Grenada 1
GN - Guinea 1
GY - Guiana 1
Totale 11.764
Salva come PNG Salva come JPEG
Città #
Singapore 1.593
Ashburn 819
San Jose 796
The Dalles 630
Dallas 390
Shanghai 281
Beijing 220
Ho Chi Minh City 192
Hong Kong 178
Chandler 117
Hanoi 109
São Paulo 77
Los Angeles 74
Boardman 71
Santa Clara 69
New York 62
Helsinki 47
Rio de Janeiro 34
Dublin 33
Brooklyn 32
London 29
Assago 28
Chennai 28
Wilmington 28
Stockholm 27
Belo Horizonte 26
Tokyo 26
Frankfurt am Main 25
Montreal 25
Brno 24
Orem 24
Curitiba 23
Da Nang 23
Warsaw 23
Paris 21
Toronto 21
Chicago 19
Amsterdam 18
Haiphong 18
Mexico City 18
Munich 18
Campinas 17
Phoenix 16
Baghdad 14
Denver 14
Johannesburg 14
Lahore 14
Milan 14
Salvador 14
Atlanta 13
Brasília 13
Council Bluffs 13
Dhaka 13
Goiânia 13
Lawrence 13
New Delhi 13
Princeton 13
Reston 13
Ankara 12
Olomouc 12
Quito 12
San Francisco 12
Baku 11
Biên Hòa 11
Brussels 11
Mumbai 11
Santo André 11
Boston 10
Moscow 10
Naples 10
San Mateo 10
Tashkent 10
Hải Dương 9
Manchester 9
Cape Town 8
Guarulhos 8
Poplar 8
São Bernardo do Campo 8
Asunción 7
Benin City 7
Betim 7
Buffalo 7
Bắc Ninh 7
Can Tho 7
Charlotte 7
Guayaquil 7
Karachi 7
Kyiv 7
Nairobi 7
Piracicaba 7
Sorocaba 7
Valparaíso de Goiás 7
Amman 6
Bogotá 6
Buenos Aires 6
Bến Tre 6
Caracas 6
Caxias do Sul 6
Fortaleza 6
Juiz de Fora 6
Totale 6.899
Salva come PNG Salva come JPEG
Nome #
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial 115
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 109
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 94
Allele *2 of the HS1,2A enhancer of the Ig regulatory region associates with rheumatoid arthritis 91
Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine 84
Access of arthritis patients to an early arthritis clinic in three different settings: the very early ra represents the best clinical and therapeutic opportunity to reach das remission. Quality indicators (QI) of the italian ministry of health program 78
Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis. 76
Proton pump inhibitors in rheumatic diseases: clinical practice, drug interactions, bone fractures and risk of infections 76
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 70
Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study 69
B cell depletion and a T cell-targeted therapy allows to control the sudden onset of diabetes and lupus, without steroids 69
A multiparametric risk table for loss of clinical remission status in patients with rheumatoid arthritis: A starter study post-hoc analysis 68
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials 68
Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA. 67
A brief battery for the evaluation of cognitive deficits in italian SLE patients 63
An unusual lung involvement in scleroderma: lipoid pneumonia 62
An autosomal recessive DNASE1L3-related autoimmune disease with unusual clinical presentation mimicking systemic lupus erythematosus 58
Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors 58
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study 58
Amplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease 57
ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature 57
A brief battery for the evaluation of cognitive deficits in italian SLE patients 57
ACPA–IL-6 as the best biomarkers to differentiate early rheumatoid arthritis from undifferentiated arthritis: analysis of the diagnostic performance 57
Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report 56
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 56
Peripheral blood B cells subsets in patients with systemic lupus erythematosus: correlation with disease activity and organ involvement 56
[Class IV-G and IV-S lupus nephritis, interstitial infiltrates and prognosis: state of the art and unmet medical needs] 56
Cancer in connective tissue disease 56
Biologics use in SLE in 23 centers – data from the international registry for biologics in SLE 55
Adult onset Still's disease and pregnancy 55
The Role of Microrna-34 and Microrna-22 in Dendritic Cells and Monocyte Activation in Rheumatoid Arthritis 55
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting 54
Abatacept in the treatment of psoriatic arthritis: biological and clinical profiles (of the responders) 53
QT and QT dispersion intervals in long-standing and moderately active rheumatoid arthritis: results from a multicentre cross-sectional study 52
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 51
B-cell directed therapy in rheumatoid arthritis: predictive factors of efficacy and assessment of regeneration profile 51
Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis 51
B-cell depletion in rheumatoid arthritis: searching for serologic and clinical baseline factors that could predict long-term efficacy 51
Anti-nucleosome antibodies: correlations with activity and chronicity disease indexes in systemic lupus erythematosus patients with renal involvement 51
Is Citrullination Required for the Presence of Restricted Clonotypes Reacting With Type II Collagen? Comment on the Article by Chemin et al 50
The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU) 49
IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy 49
Association of the 22 genotype of enhancer HS1,2A of the Ig heavy 3′ regulatory region with non response to DMARDS and response to rituximab in rheumatoid arthritis patients 49
Circulating Human Collagen II-Reactive T Cell in Early Rheumatoid Arthritis Produce IL17. 47
Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study 47
CD19+ cells subsets (CD5, CD38 and CD23) in peripheral blood and synovial fluid of rheumatoid arthritis patients: relationship with disease activity and with auto-antibody levels 47
Results of the classification criteria for cryoglobulinemic vasculitis validation study 47
Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases) 47
Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results 47
Effectiveness of SB4 Transition from Originator Etanercept in Rheumatoid Arthritis and Axial Spondyloarthritis: A Subgroup Analysis from the BENEFIT Study 47
Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years 47
Antineutrophil cytoplasmic autoantibodies (ANCA) positivity as a red flag of severe disease in lupus nephritis 46
Distribution of body mass index and metabolic syndrome in patients with inflammatory autoimmune diseases from a single italian centre 46
Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis 46
Gut microbiota analysis in systemic sclerosis according to disease characteristics and nutritional status 45
ZAP70 B Cells and Plasmablasts As Markers of Disease Activity and Remission in Systemic LUPUS Erythematosus Nephritis 45
Adult Onset Still's Disease and Radiotherapy treatment for breast cancer: Case report about management of this rare association and literature review 45
Immune-Guided Therapy of COVID-19 44
Off-label use of rituximab for SLE in Europe: a comparison to patients treated with conventional immunosuppressive medications 44
Effects of l-Arginine Plus Vitamin C Supplementation on l-Arginine Metabolism in Adults with Long COVID: Secondary Analysis of a Randomized Clinical Trial 44
Balance between hepatocyte growth factor (HGF) and transforming growth factor (TGF-BETA1) in renal biopsies of patients with lupus nephritis 44
Malnutrition in COVID-19 survivors: prevalence and risk factors 44
Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis 44
Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease 44
Positive RT-PCR nasopharyngeal swab in patients recovered from COVID-19 disease: When does quarantine really end? 43
Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype 43
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort 43
Thrombogenicity of TNF alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers 43
The body mass index: a determinant of remission in early rheumatoid arthritis 43
Tocilizumab in the treatment of arthritis: response to therapy and evaluation of B cells subsets after 4 months treatment 42
Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis 42
Perception of health status in young adult patients with Juvenile idiopatic arthritis 42
Hepatocyte growth factor (HGF)/transforming growth factor (TGF-BETA1) balance in renal biopsies and clinical outcome in patients with lupus nephritis treated with cyclophosphamide 42
Definition of fibromyalgia severity: Findings from a cross-sectional survey of 2339 Italian patients 42
Long-term survival of anti-TNF therapy in a large italian cohort of rheumatoid arthritis patients: comparison among adalimumab, etanercept, and infliximab 42
CD19+ZAP70+ B cells value at baseline predicts response at T6 to BCDT (B cell depletion therapy). Recovery is mainly characterized by the appearance of naïve activated B cells and ZAP-70 positive B cells 42
Synovial predictors of differentiation to definite arthritis in patients with seronegative undifferentiated peripheral inflammatory arthritis: MicroRNA signature, histological, and ultrasound features 42
Chemerin and PEDF are metaflammation-related biomarkers of disease activity and obesity in rheumatoid arthritis 42
The measurement of fibromyalgia severity: converting scores between the FIQR, the PSD and the FASmod 42
Early Spondyloarthritis Clinic: Organizational Improvements in the Patient Journey 42
Minimal disease activity in early and longstanding rheumatoid arthritis 41
Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial 41
Gastrointestinal involvement in systemic vasculitis 41
EFFECTIVENESS AND SAFETY OF BELIMUMAB IN PATIENTSWITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A LARGE, NATIONWIDE, MULTICENTRIC STUDY 41
Predictors, Features and Effects of First Biologic Switch in Rheumatoid Arthritis within GISEA register: Italian 10-Year Experience. 41
Functional indexes in osteoarthritis of the knee are significantly determined by the presence or not of synovitis 41
Demographic and clinical differences between ankylosing spondylitis and non-radiographic axial spondyloarthritis: results from a multicentre retrospective study in the Lazio region of Italy 41
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial 41
Long-term anti-TNF therapy and risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison among adalimumab, etanercept and infliximab 41
Anti-nucleosome antibodies: correlations with activity and chronicity disease indexes in systemic lupus erythematosus patients with renal involvement 41
Synovial tissue derived characteristics are included in a nomogram for the prediction of treatment response in naïve Rheumatoid Arthritis 40
The role of High-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on Vascular endothelial growth factor 40
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors 40
Metabolic syndrome in autoimmune diseases: prevalence and relationship with the inflammatory burden 40
Sarilumab use in severe SARS-CoV-2 pneumonia 40
Impact of commercial strain use on saccharomyces cerevisiae population structure and dynamics in pinot noir vineyards and spontaneous fermentations of a canadian Winery 40
Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA 40
Spondiloartriti sieronegative 40
Different levels of TCR-zeta chain and ZAP-70 characterize distinct subsets of T CD28null lymphocytes in arthritis patients 40
Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment 40
Totale 5.161
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.816
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.816
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 8 0 4
2021/202229 1 0 1 6 0 1 1 3 3 5 4 4
2022/2023277 28 13 28 43 21 25 0 27 45 30 16 1
2023/2024728 11 13 54 15 1 32 18 9 5 7 19 544
2024/20253.289 181 27 136 64 58 272 174 177 707 804 348 341
2025/20267.689 1.224 620 470 622 355 460 2.556 363 501 518 0 0
Totale 12.073